View Older Stories View More Recent Stories

Mar 22, 2024 07:30PM ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Banco Santander, S.A. Investors to Inquire About Securities Class Action Investigation – SAN
Mar 19, 2024 05:45PM ROSEN, SKILLED INVESTOR COUNSEL, Encourages Banco Santander, S.A. Investors to Inquire About Securities Class Action Investigation – SAN
Mar 15, 2024 05:58PM ROSEN, NATIONAL TRIAL LAWYERS, Encourages Banco Santander, S.A. Investors to Inquire About Securities Class Action Investigation – SAN
Mar 12, 2024 05:00PM ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Banco Santander, S.A. Investors to Inquire About Securities Class Action Investigation – SAN
Mar 5, 2024 07:06PM ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Banco Santander, S.A. Investors to Inquire About Securities Class Action Investigation – SAN
Mar 2, 2024 08:30AM ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Banco Santander, S.A. Investors to Inquire About Securities Class Action Investigation – SAN
Feb 22, 2024 04:28PM SAN INVESTOR NEWS: ROSEN, A LEADING LAW FIRM, Encourages Banco Santander, S.A. Investors to Inquire About Securities Class Action Investigation – SAN
Jan 29, 2024 08:00AM Synthekine Announces Strategic Collaboration with Sanofi to Develop Selective IL-10 Agonists for Treatment of Inflammatory Diseases
Sep 13, 2023 08:15AM Sanofi and rapper/actor Ice-T unveil trailer for The Season as a warning against the flu
Jul 18, 2023 10:06AM Santander Signs Jon Rahm as New Global Ambassador
May 21, 2023 02:17PM Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine
May 1, 2023 06:04AM Sanofi (SNY) and Maze Therapeutics Enter Worldwide License Agreement for MZE001
May 1, 2023 06:00AM Maze Therapeutics Announces Exclusive Worldwide License Agreement with Sanofi for MZE001, an Oral Substrate Reduction Therapy for the Treatment of Pompe Disease
Mar 23, 2023 02:00AM Press Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial 
Mar 21, 2023 02:00AM Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis 
Mar 18, 2023 10:00AM Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis
Mar 18, 2023 10:00AM Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis
Mar 13, 2023 02:00AM Press Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)
Mar 7, 2023 01:00AM Press Release: Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review
Jan 30, 2023 01:00AM Press Release:  Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitis
Jan 30, 2023 01:00AM Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis
Jan 27, 2023 01:00AM Press Release: Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis
Dec 21, 2022 05:30PM Press Release: Positive Dupixent® (dupilumab) Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine
Dec 21, 2022 05:29PM Positive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of Medicine
Dec 16, 2022 07:30AM Regeneron (REGN), Sanofi (SNY) Announces Dupixent Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis
Dec 16, 2022 07:30AM Press Release: Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis
Dec 16, 2022 07:29AM Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis
Dec 15, 2022 01:00AM Press Release: Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis
Dec 15, 2022 12:59AM Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis
Dec 6, 2022 12:00AM Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing
Nov 11, 2022 07:00AM Press Release: Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of prurigo nodularis
Nov 11, 2022 06:59AM Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis
Oct 11, 2022 01:00AM Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data presented at UEG Week 2022 showed significant histological remission of eosinophilic esophagitis (EoE) in children 1 to 11 years old
Oct 11, 2022 12:59AM Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old
Sep 28, 2022 06:05PM Press Release: Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis
Sep 28, 2022 05:46PM Regeneron (REGN), Sanofi (SNY) Announce FDA Approval for Dupixent to Treat Prurigo Nodularis
Sep 28, 2022 05:44PM Dupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis
Sep 15, 2022 06:38PM Positive Dupixent® (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Published in The Lancet
Sep 8, 2022 11:30AM Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data at EADV 2022 showed significant improvements in signs and symptoms of prurigo nodularis
Sep 8, 2022 11:29AM Regeneron (REGN) Says Dupixent Late-breaking Phase 3 Data at the EADV 2022 Congress Showed Significant Improvements in Signs and Symptoms of Prurigo Nodularis
Sep 8, 2022 11:29AM Dupixent® (dupilumab) Late-breaking Phase 3 Data at the EADV 2022 Congress Showed Significant Improvements in Signs and Symptoms of Prurigo Nodularis
Sep 5, 2022 07:29AM Late-Breaking Dupixent® (dupilumab) Data at ERS 2022 Show Consistent Efficacy and Safety Profile for Up to Two Years in Children Aged 6 to 11 Years with Moderate-to-severe Asthma
Sep 5, 2022 01:30AM Press Release: Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma
Aug 16, 2022 08:07AM Apex Clean Energy Secures Financing for 224 MW Great Pathfinder Wind
Aug 2, 2022 07:57AM Apex Clean Energy Accelerates Transition to IPP Through Refinancing
Jul 14, 2022 01:00AM Press Release: Dupixent® (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis
Jun 7, 2022 04:45PM Press Release: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
Jun 7, 2022 04:44PM Regeneron (REGN) Announces FDA Approval of Dupixent for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis
Jun 7, 2022 04:44PM FDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis
May 31, 2022 01:00AM Press Release: FDA accepts Dupixent® (dupilumab) for priority review in adults with prurigo nodularis
View More Recent Stories View Older Stories